Evidence map›Paper›PMID 35111539›Full record

ArticleFujita medical journal2021

Circulating miR-489 as a potential new biomarker for idiopathic dilated cardiomyopathy.

Tomoya Ishiguro, Mutsuharu Hayashi, Wakaya Fujiwara, Satoshi Okumura, Masataka Yoshinaga, Ryo Yamada, Sayano Ueda, Takehiro Ito, Yudai Niwa, Akane Miyazaki and 5 more

Open access · greenAbstract read
In one paragraph

Article in Fujita medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Tomoya IshiguroDepartment of Cardiology, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.
Mutsuharu HayashiDepartment of Cardiology, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.
Wakaya FujiwaraDepartment of Cardiology, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.
Satoshi OkumuraDepartment of Cardiology, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.
Masataka YoshinagaDepartment of Cardiology, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.
Ryo YamadaDepartment of Cardiology, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.
Sayano UedaDepartment of Cardiology, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.
Takehiro ItoDepartment of Cardiology, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.
Yudai NiwaDepartment of Cardiology, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.
Akane MiyazakiDepartment of Cardiology, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.
Masahide HaradaDepartment of Cardiology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Hiroyuki NaruseDepartment of Cardiology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Junnichi IshiiDepartment of Cardiology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Yukio OzakiDepartment of Cardiology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Hideo IzawaDepartment of Cardiology, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.
Fujita Health University Hospital · JPFujita Health University Bantane HospitalFujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesMicroRNAs (miRNA) are functional RNAs that have emerged as pivotal gene expression regulators in cardiac disease. Although several cardiomyocyte miRNAs have been reported to play roles in heart failure progression among patients with idiopathic dilated cardiomyopathy (DCM), the role of circulating miRNAs has not yet been well-examined.

methodsAfter total RNA extraction from the peripheral blood samples of three control participants and six patients with DCM, miRNA profiling was performed using miRNA arrays. Based on the results of this initial screening, real-time polymerase chain reaction (RT-PCR) was used to perform a quantitative analysis of blood samples from a larger number of matched patients (DCM,

resultsA primary screening of 2,565 miRNAs resulted in the identification of nine miRNA candidates. Quantitative RT-PCR results revealed significantly increased miR-489 expression levels in the DCM group. Moreover, there was a significant positive correlation between miR-489 expression level and left ventricular ejection fraction.

conclusionsOur results suggest that circulating miR-489 could be a potential noninvasive diagnostic biomarker for DCM. Additionally, the quantification of circulating miR-489 may have value as a potential prognostic marker for patients with DCM.

Indexed as

BiomarkerDilated cardiomyopathy (DCM)MicroarrayMicroRNA

Identifiers

PMID35111539
PMCPMC8749486
OpenAlexW3127132824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.